Summary BNF Drug Summaries - Cardiovascular System

Drug Summaries – Humza Ibrahim
4.2.2 Long-term management ...................... 6
Chapter 2 5 Warfarin (high risk) .............................................. 7
Cardiovascular System 5.1 Target inr...................................................... 7
5.2 Duration ....................................................... 7

TABLE OF CONTENTS 5.3 Warning sings............................................... 7
5.4 Monitoring ................................................... 7
Table of Contents ......................................................... 1
5.5 Pregnancy and breastfeeding ...................... 7
1 Arrhythmias.......................................................... 3
5.6 Interactions .................................................. 7
1.1 Drugs for arrhythmias .................................. 3
5.7 Hepatic impairment ..................................... 7
1.1.1 Drug treatment .................................... 3
5.8 Renal impairment ........................................ 7
1.1.2 Cardioversion ....................................... 3
5.9 Other points ................................................. 7
1.1.3 Stroke prevention ................................ 3
6 Antiplatelet drugs ................................................ 8
1.2 Amiodarone (high risk)................................ 4
6.1 Aspirin .......................................................... 8
1.2.1 Warning signs ....................................... 4
6.1.1 Reye's syndrome (liver and brain
1.2.2 Monitoring ........................................... 4 damage) 8
1.2.3 Pregnancy............................................. 4 6.1.2 Hypersensitivity ................................... 8
1.2.4 Breastfeeding ....................................... 4 6.2 Oral antiplatelets (high risk) ....................... 8
1.2.5 Drug Interactions ................................. 4 6.2.1 Warning signs....................................... 8
1.3 Sotalol .......................................................... 4 6.2.2 Monitoring ........................................... 8
1.3.1 Safety information ............................... 4 6.2.1 Other points ......................................... 8
1.3.2 Monitoring ........................................... 4 6.2.2 Interactions .......................................... 8
2 Cardiac Glycosides ............................................... 5 7 Hypertension ....................................................... 8
2.1 Digoxin (High Risk)....................................... 5 7.1 Thresholds.................................................... 8
2.1.1 Warning signs ....................................... 5 7.2 Targets for treatment .................................. 9
2.1.2 Monitoring ........................................... 5 7.3 Drug treatment (NICE 2107) ........................ 9
2.1.3 Renal impairment................................. 5 7.4 Reducing cardiovascular risk........................ 9
2.1.4 Drug interactions.................................. 5 7.5 Diabetes and renal disease .......................... 9
3 Venous Thromboembolism .................................. 5 7.6 Hypertension and pregnancy....................... 9
3.1 Prophylaxis ................................................... 5 7.7 Hypertensive crisis ....................................... 9
3.2 Treatment .................................................... 5 7.8 Antihypertensives (high risk) ...................... 9
3.3 Pregnancy..................................................... 5 7.8.1 Warning signs....................................... 9
3.4 Haemorrhage ............................................... 6 7.8.2 Monitoring ........................................... 9
3.5 Heparin......................................................... 6 7.8.3 Interactions .......................................... 9
3.5.1 Heparin-induced thrombocytopenia ... 6 7.8.4 Other points ......................................... 9
3.5.2 Hyperkalaemia ..................................... 6 7.9 Drugs affecting the renin-angiotensin
4 Stroke ................................................................... 6 system 10

4.1 Transient ischaemic attack........................... 6 7.9.1 Initiation under specialist supervision10

4.2 Ischaemic stroke .......................................... 6 7.9.2 Renal effects ...................................... 10

4.2.1 Initial management .............................. 6 7.9.3 Cautions ............................................. 10
7.10 Beta-adrenoceptor blocking drugs ............ 10
Chapter 2 – Pg 1
Compiled using the British National Formulary

, Drug Summaries – Humza Ibrahim
7.11 Calcium channel blockers........................... 11
7.12 Hypotension and shock .............................. 11
8 Heart failure ....................................................... 11
9 Hyperlipidaemia ................................................. 11
9.1 Risk calculators........................................... 11
9.2 Primary and secondary prevention of
cardiovascular disease ........................................... 11
9.3 Cholesterol tests ........................................ 12
9.4 Hypercholesterolaemia,
hypertriglyceridaemia, and familial
hypercholesterolaemia .......................................... 12
9.5 Statins......................................................... 12
10 Stable angina ...................................................... 12
11 Acute coronary syndromes (ACS) ...................... 12
11.1 Initial management of unstable angina,
nstemi and stemi.................................................... 12
11.1.1 Additional acute management of
unstable angina, NSTEMI ................................... 13
11.1.2 Additional acute management of STEMI
13
11.2 Long-term management ACS ..................... 13
11.3 Nitrates....................................................... 13
11.4 Fibrinolytics ................................................ 13
12 Oedema .............................................................. 13
12.1 Elderly ........................................................ 13
12.2 Potassium loss ............................................ 13
12.3 Urinary retention ....................................... 13
12.4 Diabetes and gout ...................................... 13
12.5 Diuretics (high risk).................................... 14
12.5.1 Warning signs ..................................... 14
12.5.2 Monitoring ......................................... 14
12.5.3 Other points ....................................... 14
12.5.4 Interactions ........................................ 14




Chapter 2 – Pg 2
Compiled using the British National Formulary